Back
For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".
To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".
During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center.
Preparing your E-Poster
Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.
E-Poster Submission Deadline
Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.
Please follow the instructions below to input your abstract title.
Abstract titles should be brief and reflect the content of the abstract.
Epidemiological and clinical studies have demonstrated a correlation between elevated serum hyperuricemia (SUA) and cardiovascular disease (CVD). Currently, there is limited and conflicting evidence regarding the association between SUA levels and cardiovascular events in the dialysis population. Whether urate-lowering therapy can improve cardiovascular outcomes in peritoneal dialysis (PD) patients remains an important and unanswered clinical question.
A multicenter, double-blind, randomized controlled trial involving maintenance PD patients with asymptomatic hyperuricemia was conducted. Patients were randomly assigned to receive febuxostat (40mg daily) or placebo. The primary outcome was cardiovascular events including cardiovascular mortality and non-fatal cardiovascular events. Secondary outcomes were all-cause mortality, cardiovascular mortality and non-fatal cardiovascular events, respectively.
A total of 527 underwent randomization with 262 patients received febuxostat and 265 received placebo and were followed for a median of 24.05 (10.87~35.38) months. A primary outcome occurred in 21 patients (8.0%) in the febuxostat group and in 24 patients (9.0%) in the placebo group (hazard ratio, 0.82; 95% confidence interval [CI], 0.46-1.48; P=0.51). With regard to the all-cause mortality, and non-fatal cardiovascular events, there were no significant differences between febuxostat and placebo (hazard ratio for all-cause mortality, 0.67 [95% CI, 0.30 to 1.51], P=0.33; hazard ratio for non-fatal cardiovascular events, 0.65 [95% CI, 0.35 to 1.24], P=0.19;). For cardiovascular mortality, there were only 5 events in febuxostat group and 1 event in placebo group, the events were not enough to perform comparable analysis between groups. In subgroup analysis, patients with age ≥50 years old had lower risks in febuxostat than placebo group for all-cause mortality and the composite outcomes of all-cause mortality and cardiovascular disease (hazard ratio for all-cause mortality in aged≥50 years old , 0.27 [95% CI, 0.07 to 1.00], P=0.036; hazard ratio for composite outcomes of all-cause mortality and cardiovascular disease in aged≥50 years old, 0.46 [95% CI, 0.23 to 0.94], P=0.029). There was no significant difference between febuxostat and placebo groups in different gender and uric acid levels pertaining to primary or secondary outcomes.
End point
Febuxostat
(n=262)
Placebo (n=265)
Hazard Ratio
(95%CI)
P value
no. of patients (%)
Primary endpoint: composite of cardiovascular mortality and non-fatal cardiovascular events
21 (8.0%)
24(9.0%)
0.82(0.46-1.48)
0.51
Secondary endpoints
all-cause death
10 (3.8%)
14(5.3%)
0.67(0.30-1.51)
0.33
cardiovascular death
5 (1.9%)
1(0.4%)
4.69(0.55-40.17)
0.12
non-fatal cardiovascular events
16(6.1)
23(8.7%)
0.65(0.35-1.24)
0.19
In PD patients with asymptomatic hyperuricemia, urate lowering treatment with febuxostat did not reduce the risk of cardiovascular event as compared with placebo. However, patients with age ≥50 years old had lower risks in febuxostat than placebo group for all-cause mortality and the composite outcomes of all-cause mortality and cardiovascular disease.
